Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

An approach to the patient with drug allergy

Werner J Pichler, MD
Section Editor
N Franklin Adkinson, Jr, MD
Deputy Editor
Anna M Feldweg, MD


The onset of hives within a few hours of taking a new medication is easily recognized as possible drug hypersensitivity. However, many clinical presentations of drug hypersensitivity are more complex or take place in the setting of illness and/or polypharmacotherapy. The patient in intensive care who develops a rash while receiving multiple medications, or the ambulatory patient with complex chronic diseases who develops a new and unexplained symptom while taking many medications, illustrates two common presentations of drug allergy.

The main questions that arise in such situations include the following:

Is the adverse event related to a drug?

If so, which drug is responsible?

Is the reaction due to an immune response to the drug (ie, true drug allergy) or due to another mechanism, such as pseudoallergy? (See 'Drug pseudoallergy' below.)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Apr 10, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Demoly P, Viola M, Rebelo Gomes E, Romano A. Epidemiology and causes of drug hypersensitivity. In: Drug hypersensitivity, Pichler WJ (Ed), Karger Basel, Switzerland 2007. p.2.
  2. Sullivan TJ, Remedios C, Ong MD, Gilliam LK. Studies of the multiple drug allergy syndrome. J Allergy Clin Immunol 1989; 83:270.
  3. Moseley EK, Sullivan TJ. Allergic reactions to antimicrobial drugs in patients with a history of prior drug allergy. J Allergy Clin Immunol 1991; 87:226 (Abstract).
  4. Asero R, Tedeschi A, Lorini M, et al. Sera from patients with multiple drug allergy syndrome contain circulating histamine-releasing factors. Int Arch Allergy Immunol 2003; 131:195.
  5. Sullivan TJ. Management of patients allergic to antimicrobial drugs. Allergy Proc 1991; 12:361.
  6. Kamada MM, Twarog F, Leung DY. Multiple antibiotic sensitivity in a pediatric population. Allergy Proc 1991; 12:347.
  7. Gex-Collet C, Helbling A, Pichler WJ. Multiple drug hypersensitivity--proof of multiple drug hypersensitivity by patch and lymphocyte transformation tests. J Investig Allergol Clin Immunol 2005; 15:293.
  8. Daubner B, Groux-Keller M, Hausmann OV, et al. Multiple drug hypersensitivity: normal Treg cell function but enhanced in vivo activation of drug-specific T cells. Allergy 2012; 67:58.
  9. Moss RB, Babin S, Hsu YP, et al. Allergy to semisynthetic penicillins in cystic fibrosis. J Pediatr 1984; 104:460.
  10. Avila PC, Kishiyama JL. Allergic manifestations in AIDS. Clin Rev Allergy Immunol 1996- 1997; 14:433.
  11. Kurtz KM, Beatty TL, Adkinson NF Jr. Evidence for familial aggregation of immunologic drug reactions. J Allergy Clin Immunol 2000; 105:184.
  12. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.
  13. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007; 7:317.
  14. Chessman D, Kostenko L, Lethborg T, et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008; 28:822.
  15. Wu Y, Farrell J, Pirmohamed M, et al. Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 2007; 119:973.
  16. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364:1134.
  17. Genin E, Chen DP, Hung SI, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J 2014; 14:281.
  18. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102:4134.
  19. Yun J, Marcaida MJ, Eriksson KK, et al. Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01. J Immunol 2014; 192:2984.
  20. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727.
  21. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568.
  22. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther 2009; 13:1.
  23. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41:816.
  24. Pompeu YA, Stewart JD, Mallal S, et al. The structural basis of HLA-associated drug hypersensitivity syndromes. Immunol Rev 2012; 250:158.
  25. Zhang FR, Liu H, Irwanto A, et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med 2013; 369:1620.
  26. Cameron SJ, Richmond J. Ampicillin hypersensitivity in lymphatic leukaemia. Scott Med J 1971; 16:425.
  27. Kerns D, Shira JE, Go S, et al. Ampicillin rash in children. Relationship to penicillin allergy and infectious mononucleosis. Am J Dis Child 1973; 125:187.
  28. Carr A, Swanson C, Penny R, Cooper DA. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993; 167:180.
  29. Daftarian MP, Filion LG, Cameron W, et al. Immune response to sulfamethoxazole in patients with AIDS. Clin Diagn Lab Immunol 1995; 2:199.
  30. Rose EW, McCloskey WW. Glutathione in hypersensitivity to trimethoprim/sulfamethoxazole in patients with HIV infection. Ann Pharmacother 1998; 32:381.
  31. Lanctôt KL, Ghajar BM, Shear NH, Naranjo CA. Improving the diagnosis of hypersensitivity reactions associated with sulfonamides. J Clin Pharmacol 1994; 34:1228.
  32. Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem Res Toxicol 1999; 12:387.
  33. Idée JM, Pinès E, Prigent P, Corot C. Allergy-like reactions to iodinated contrast agents. A critical analysis. Fundam Clin Pharmacol 2005; 19:263.
  34. Caubet JC, Kaiser L, Lemaître B, et al. The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. J Allergy Clin Immunol 2011; 127:218.
  35. Adkinson NF Jr. Risk factors for drug allergy. J Allergy Clin Immunol 1984; 74:567.
  36. Idsoe O, Guthe T, Willcox RR, de Weck AL. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bull World Health Organ 1968; 38:159.
  37. Kano Y, Hirahara K, Mitsuyama Y, et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007; 62:1439.
  38. Messaad D, Sahla H, Benahmed S, et al. Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann Intern Med 2004; 140:1001.
  39. Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58:854.
  40. Florvaag E, Johansson SG. The pholcodine story. Immunol Allergy Clin North Am 2009; 29:419.
  41. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358:1109.
  42. Commins SP, Satinover SM, Hosen J, et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol 2009; 123:426.
  43. Schwartz LB, Metcalfe DD, Miller JS, et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987; 316:1622.
  44. Empedrad R, Darter AL, Earl HS, Gruchalla RS. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol 2003; 112:629.
  45. Himly M, Jahn-Schmid B, Pittertschatscher K, et al. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J Allergy Clin Immunol 2003; 111:882.
  46. Adkinson NF Jr. Tests for immunological reactions to drugs and occupational allergens. In: Manual of clinical laboratory immunology, Rose NR, Conway de Macario E, Folds JD, et al (Eds), American Society of Microbiology, Washington, DC 1997. p.893.
  47. Schmid DA, Campi P, Pichler WJ. Hypersensitivity reactions to quinolones. Curr Pharm Des 2006; 12:3313.
  48. Manfredi M, Severino M, Testi S, et al. Detection of specific IgE to quinolones. J Allergy Clin Immunol 2004; 113:155.
  49. Fontaine C, Mayorga C, Bousquet PJ, et al. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy. Allergy 2007; 62:47.
  50. Kleine-Tebbe J, Erdmann S, Knol EF, et al. Diagnostic tests based on human basophils: potentials, pitfalls and perspectives. Int Arch Allergy Immunol 2006; 141:79.
  51. Ebo DG, Sainte-Laudy J, Bridts CH, et al. Flow-assisted allergy diagnosis: current applications and future perspectives. Allergy 2006; 61:1028.
  52. Kvedariene V, Kamey S, Ryckwaert Y, et al. Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils. Allergy 2006; 61:311.
  53. Ebo DG, Bridts CH, Hagendorens MM, et al. Flow-assisted diagnostic management of anaphylaxis from rocuronium bromide. Allergy 2006; 61:935.
  54. Sanz ML, Gamboa PM, Antépara I, et al. Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics. Clin Exp Allergy 2002; 32:277.
  55. Gamboa P, Sanz ML, Caballero MR, et al. The flow-cytometric determination of basophil activation induced by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome. Clin Exp Allergy 2004; 34:1448.
  56. Gamboa PM, Sanz ML, Caballero MR, et al. Use of CD63 expression as a marker of in vitro basophil activation and leukotriene determination in metamizol allergic patients. Allergy 2003; 58:312.
  57. Malbrán A, Yeyati E, Rey GL, Galassi N. Diclofenac induces basophil degranulation without increasing CD63 expression in sensitive patients. Clin Exp Immunol 2007; 147:99.
  58. Sanz ML, Gamboa P, de Weck AL. A new combined test with flowcytometric basophil activation and determination of sulfidoleukotrienes is useful for in vitro diagnosis of hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2005; 136:58.
  59. Yawalkar N, Pichler WJ. Immunohistology of drug-induced exanthema: clues to pathogenesis. Curr Opin Allergy Clin Immunol 2001; 1:299.
  60. Romano A, Blanca M, Torres MJ, et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy 2004; 59:1153.
  61. Beeler A, Engler O, Gerber BO, Pichler WJ. Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J Allergy Clin Immunol 2006; 117:455.
  62. Barbaud A. Skin testing in delayed reactions to drugs. Immunol Allergy Clin North Am 2009; 29:517.
  63. Wolkenstein P, Chosidow O, Fléchet ML, et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996; 35:234.
  64. Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol 2013; 168:555.
  65. Romano A, Quaratino D, Di Fonso M, et al. A diagnostic protocol for evaluating nonimmediate reactions to aminopenicillins. J Allergy Clin Immunol 1999; 103:1186.
  66. Stejskal VD, Olin RG, Forsbeck M. The lymphocyte transformation test for diagnosis of drug-induced occupational allergy. J Allergy Clin Immunol 1986; 77:411.
  67. Gruchalla RS, Sullivan TJ. In vivo and in vitro diagnosis of drug allergy. Immunology Allergy Clin North America 1991; 11:595.
  68. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997; 27:175.
  69. Sachs B, Erdmann S, Malte Baron J, et al. Determination of interleukin-5 secretion from drug-specific activated ex vivo peripheral blood mononuclear cells as a test system for the in vitro detection of drug sensitization. Clin Exp Allergy 2002; 32:736.
  70. Brugnolo F, Annunziato F, Sampognaro S, et al. Highly Th2-skewed cytokine profile of beta-lactam-specific T cells from nonatopic subjects with adverse drug reactions. J Immunol 1999; 163:1053.
  71. Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002; 109:155.
  72. Zawodniak A, Lochmatter P, Yerly D, et al. In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases. Allergy 2010; 65:376.
  73. Porebski G, Pecaric-Petkovic T, Groux-Keller M, et al. In vitro drug causality assessment in Stevens-Johnson syndrome - alternatives for lymphocyte transformation test. Clin Exp Allergy 2013; 43:1027.
  74. Vaillant L, Camenen I, Lorette G. Patch testing with carbamazepine: reinduction of an exfoliative dermatitis. Arch Dermatol 1989; 125:299.
  75. Scherer K, Brockow K, Aberer W, et al. Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68:844.
  76. Romano A, Gaeta F, Valluzzi RL, et al. Diagnosing nonimmediate reactions to cephalosporins. J Allergy Clin Immunol 2012; 129:1166.
  77. Borch JE, Bindslev-Jensen C. Full-course drug challenge test in the diagnosis of delayed allergic reactions to penicillin. Int Arch Allergy Immunol 2011; 155:271.
  78. Blanca-López N, Zapatero L, Alonso E, et al. Skin testing and drug provocation in the diagnosis of nonimmediate reactions to aminopenicillins in children. Allergy 2009; 64:229.
  79. Schnyder B, Pichler WJ. Nonimmediate drug allergy: diagnostic benefit of skin testing and practical approach. J Allergy Clin Immunol 2012; 129:1170.
  80. Misirlioglu ED, Toyran M, Capanoglu M, et al. Negative predictive value of drug provocation tests in children. Pediatr Allergy Immunol 2014; 25:685.
  81. Demoly P, Romano A, Botelho C, et al. Determining the negative predictive value of provocation tests with beta-lactams. Allergy 2010; 65:327.
  82. MacLaughlin EJ, Saseen JJ, Malone DC. Costs of beta-lactam allergies: selection and costs of antibiotics for patients with a reported beta-lactam allergy. Arch Fam Med 2000; 9:722.
  83. Borch JE, Andersen KE, Bindslev-Jensen C. The prevalence of suspected and challenge-verified penicillin allergy in a university hospital population. Basic Clin Pharmacol Toxicol 2006; 98:357.
  84. Kraemer MJ, Caprye-Boos H, Berman HS. Increased use of medical services and antibiotics by children who claim a prior penicillin sensitivity. West J Med 1987; 146:697.
  85. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442.
  86. Lee CE, Zembower TR, Fotis MA, et al. The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch Intern Med 2000; 160:2819.
  87. Solensky R, Earl HS, Gruchalla RS. Clinical approach to penicillin-allergic patients: a survey. Ann Allergy Asthma Immunol 2000; 84:329.
  88. Puchner TC Jr, Zacharisen MC. A survey of antibiotic prescribing and knowledge of penicillin allergy. Ann Allergy Asthma Immunol 2002; 88:24.
  89. Kwan T, Lin F, Ngai B, Loeb M. Vancomycin use in 2 Ontario tertiary care hospitals: a survey. Clin Invest Med 1999; 22:256.
  90. Cieslak PR, Strausbaugh LJ, Fleming DW, Ling JM. Vancomycin in Oregon: who's using it and why. Infect Control Hosp Epidemiol 1999; 20:557.
  91. Bonafede M, Rice LB. Emerging antibiotic resistance. J Lab Clin Med 1997; 130:558.
  92. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342:710.
  93. Rao GG. Risk factors for the spread of antibiotic-resistant bacteria. Drugs 1998; 55:323.
  94. Martínez JA, Ruthazer R, Hansjosten K, et al. Role of environmental contamination as a risk factor for acquisition of vancomycin-resistant enterococci in patients treated in a medical intensive care unit. Arch Intern Med 2003; 163:1905.
  95. Pichler WJ, Daubner B, Kawabata T. Drug hypersensitivity: flare-up reactions, cross-reactivity and multiple drug hypersensitivity. J Dermatol 2011; 38:216.